Mariner
CHRS icon

Mariner’s Coherus Oncology CHRS Stock Holding History

Mariner’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73K Buy
52,167
+25,428
+95% +$41.5K ﹤0.01% 3372
2026
Q1 		$45.1K Buy
26,739
+15,849
+146% +$28.1K ﹤0.01% 3436
2025
Q4 		$15.4K Buy
+10,890
New +$15.9K ﹤0.01% 3500
2025
Q1 		– Sell
-10,000
Closed -$13.8K – 3464
2024
Q4 		$13.8K Hold
10,000
– – ﹤0.01% 3356
2024
Q3 		$10.4K Hold
10,000
– – ﹤0.01% 3267
2024
Q2 		$17.3K Hold
10,000
– – ﹤0.01% 3115
2024
Q1 		$23.9K Hold
10,000
– – ﹤0.01% 3083
2023
Q4 		$33.3K Buy
+10,000
New +$26.8K ﹤0.01% 2972

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Mariner's CHRS Position: Q2 2026 in Review

Mariner increased its Coherus Oncology (CHRS) stake by 95% in Q2 2026, buying an estimated $41.5K and bringing the position to 52,167 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #3372.

Mariner first reported a position in CHRS in Q4 2023 and has held it in 8 quarters since. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Mariner held 52,167 shares of Coherus Oncology worth $73K as of Q2 2026.
  • Mariner bought 25,428 Coherus Oncology shares in Q2 2026, an estimated $41.5K.
  • Coherus Oncology made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3372 holding.
  • Mariner first reported a position in Coherus Oncology in Q4 2023 and has held it in 8 quarters since.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.